SCHEMBL25310346

SCHEMBL25310346

O=C(c1cccc(-c2nc3ccccc3[nH]2)n1)N1CCN(CCO)CC1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LANCL2 Q9NS86 1/20 0.81
HRH4 Q9H3N8 2/20 0.46
DRD3 P35462 5/20 0.46
DRD2 P14416 3/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
AKR1C3 P42330 1/20 0.42
LMNA P02545 2/20 0.42
TSHR P16473 2/20 0.42
SYK P43405 1/20 0.41
DRD4 P21917 1/20 0.40
MAPT P10636 1/20 0.40
ACHE P22303 1/20 0.40
HTR2B P41595 1/20 0.40
NPC1 O15118 2/20 0.40
PKM P14618 2/20 0.40
HPGD P15428 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Omilancor SCHEMBL17706588 0.90 LANCL2 (1.00) LANCL2HRH4MEN1KMT2ALMNA
Omilancor SCHEMBL29349469 0.90 LANCL2 (1.00) LANCL2HRH4MEN1KMT2ALMNA
SCHEMBL23561738 0.88 LANCL2 (0.83) LANCL2HRH4DRD3DRD2MEN1
SCHEMBL23561754 0.87 LANCL2 (0.73) LANCL2HRH4DRD3DRD2MEN1
SCHEMBL21043129 0.87 LANCL2 (0.93) LANCL2HRH4MEN1KMT2ALMNA
SCHEMBL23561758 0.85 LANCL2 (0.70) LANCL2HRH4DRD3DRD2MEN1
SCHEMBL23522644 0.85 LANCL2 (0.76) LANCL2HRH4DRD3DRD2MEN1
SCHEMBL17705594 0.84 LANCL2 (0.88) LANCL2HRH4MEN1KMT2ALMNA
SCHEMBL18805072 0.84 LANCL2 (0.88) LANCL2HRH4MEN1KMT2ALMNA
SCHEMBL29466338 0.83 LANCL2 (0.86) LANCL2HRH4MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2024-03-28 US disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
WO-2022057932-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-03-24 WO disclosed
WO-2022057928-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LANCL2, CBS, LCP2 LANCL2 1/4885HRH4 2379/4885DRD3 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.